Top Companies in the Intratumoral Cancer Therapies Market

The global intratumoral cancer therapies market size was valued at USD 189.73 billion in 2023, driven by the rising prevalence of cancer diseases and the geriatric population across the globe. The market is expected to grow at a CAGR of 10% during the forecast period of 2024-2032, with the values likely to rise from USD 208.62 billion in 2024 to USD 445.77 billion by 2032.

Cancer is a critical condition causing millions of deaths each year. As per the latest estimates released by the International Agency for Research on Cancer (IARC), in 2022, 20 million new cancer cases were registered, and 9.7 million deaths due to cancer were reported. The leading type of cancer is lung cancer followed by colorectal cancer, liver cancer, breast cancer, and stomach cancer. The antitumoral therapies market is growing due to the increasing incidence of cancer worldwide. Intratumoral therapy involves deploying antibodies into the tumor mass to trigger and strengthen an antitumor immune response. It stimulates local immunity against the tumor by utilising it as the source of its vaccine. It also stimulates adaptive, polyclonal immunity against clinically established tumor-specific antigens (TSA) or tumor-associated antigens (TAA).

The market is witnessing various trends influencing market growth and development including the rising preference for combination therapies. Combination therapy when used in conjugation with immunotherapy, chemotherapy, and radiation therapy is expected to enhance therapeutic effectiveness and patient outcomes. Due to its effectiveness, it is gaining traction among patients and healthcare providers to develop more effective and personalised therapies. Researchers are currently trying to explore the potential impact of this approach through rigorous clinical trials. Moreover, the escalating demand for antitumoral therapies highlights a pivotal milestone. The global intratumoral cancer therapies market is rapidly shifting towards utilising patient characteristics like genetic makeup, tumor type, and response to previous treatment.

In April 2024, Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™ (an in situ personalised therapy optimised for solid tumor cancers) announced positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial was intended to treat metastatic castrate-resistant prostate cancer (mCRPC) and showed an overall ORR of 85% in the patients. 

In January 2022, Bristol-Myers Squibb announced that the Japanese Ministry of Health, Labour, and Welfare approved Abecma, which is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for use in adults with relapsed and refractory multiple myeloma who have undergone at least three prior therapies. Abecma was the first licensed CAR T cell therapy for treating R/R multiple myeloma in Japan. Additionally, in Feb 2024, a team of researchers at UF Health Cancer Center developed a first-of-its-kind compound proteolysis-targeting chimera, or PROTAC, to target NR4A1. The compound is poised to open new opportunities for using immunotherapy to treat a wide range of cancers. The approach of the compound to target protein cells inside rather than surface proteins has huge potential in treating patients who weren’t responsive to previous treatments.

Top Companies Leading the Intratumoral Cancer Therapies Market in 2024

1.    Amgen Inc.

Amgen Inc. is a dominating biotechnology company focused on human therapeutics. The company’s portfolio includes biologics for oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen develops innovative cancer treatments like IMLYGIC® (talimogene laherparepvec), a genetically modified oncolytic viral therapy.

2.    AstraZeneca

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company. The company’s oncology portfolio includes treatments for various cancers, emphasising precision medicine. In intratumoral cancer therapies, AstraZeneca's Imfinzi® (durvalumab) is being explored for local tumor treatment.

3.    Bayer AG

Bayer AG is a German pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Bayer has an impressive portfolio covering areas such as pharmaceuticals, consumer healthcare products, agricultural chemicals, seeds, and biotechnology products. The company’s oncology portfolio includes targeted therapies and radiopharmaceuticals. In intratumoral cancer therapies, Bayer's Stivarga® (regorafenib) and radiotherapy solutions are under research for direct tumor administration.

4.    Bristol-Myers Squibb Belgium SA

Bristol-Myers Squibb Belgium SA focuses on biopharmaceutical innovations, particularly in oncology. Their portfolio includes immuno-oncology drugs like Opdivo® (nivolumab) and Yervoy® (ipilimumab). In intratumoral therapies, these drugs are being investigated for direct tumor injections.

5.    Pfizer, Inc.

Pfizer is an American multinational pharmaceutical and biotechnology corporation. The company specialises in medicine and vaccine development in immunology, oncology, cardiology, endocrinology, and neurology. Their products include targeted therapies, immunotherapies, and biosimilars. In the intratumoral cancer therapies market, Pfizer is exploring innovative delivery methods for drugs like Bavencio® (avelumab).

6.    Novartis AG

Novartis AG is a multinational healthcare company known for its oncology division. The company’s portfolio includes targeted therapies, cell therapies, and immunotherapies. Novartis' Kymriah® (tisagenlecleucel) is being researched for intratumoral applications in treating solid tumors.

7.    Johnson & Johnson Inc.

Headquartered in New Jersey, USA, Johnson & Johnson is a multinational pharmaceutical, biotechnology, and medical technologies conglomerate specialising in surgical instruments and technologies.

8.    Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical leader with a robust oncology portfolio. The company’s products include targeted therapies and immunotherapies. In the intratumoral cancer therapies market, Eli Lilly is developing localised treatment methods for its cancer drugs like Cyramza® (ramucirumab).